Trellus Health (LSE:TRLS) reported continued operational progress across its core business lines, with particular momentum in clinical trials. During the period, the company secured 12-month agreements with global contract research organisations ICON and PSI to deploy its Trellus TrialSet™ platform in immunology and inflammation studies sponsored by Takeda and Sanofi. Trellus also continues to support a Phase 2 inflammatory bowel disease trial run by AstraZeneca, reinforcing its growing footprint in the clinical research space.
Beyond trials, the group made further progress across pharmaceutical and patient support programmes. This included ongoing collaboration with Johnson & Johnson Health Care Systems and the renewal of a content licensing agreement with Pfizer. At the same time, Trellus broadened its patient enrolment channels and continued to explore additional routes to scale adoption across its platforms.
Product development remains a key focus. The company is enhancing TrialSet™ to make it condition-agnostic, while upgrading its Trellus Elevate® platform and strengthening data protection and regulatory compliance. Management said these initiatives further position Trellus as a scalable digital health partner for pharmaceutical companies and CROs seeking to improve trial efficiency, patient engagement and long-term outcomes.
On the financial side, Trellus expects revenue of around $545,000 for 2025 and has reduced monthly cash burn to approximately $400,000. The group has drawn on a £5m convertible facility from Alumni Capital, extending its cash runway into late Q1 2026. The board said it continues to pursue additional funding while aiming to translate increasing clinical and commercial validation into wider market adoption.
The investment outlook remains constrained by ongoing losses, negative free cash flow and declining equity, although the absence of debt provides some balance sheet flexibility. Technical indicators are a relative positive, with the share price showing strong momentum above key moving averages, but valuation remains pressured by loss-making operations and the lack of a dividend.
More about Trellus Health PLC
Trellus Health PLC is a UK- and US-based digital health company focused on value-based solutions for complex chronic conditions, initially targeting high-cost gastrointestinal diseases such as inflammatory bowel disease. Its core product, Trellus Elevate®, combines behavioural science, data analytics, coaching and education to support whole-person condition management, while Trellus TrialSet™ applies the same technology to improve clinical trial recruitment, adherence and long-term patient engagement for pharmaceutical and CRO partners.
Leave a Reply